Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function

NCT07527195 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07527195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07527195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of CagriSema, Semaglutide and Cagrilintide on Skeletal Muscle Insulin Sensitivity, Composition and Function
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Recruiting
Start date
April 10, 2026
Completion date
June 9, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity